Motilal Oswal Alternates has announced an investment of $72 million in Sensa Core Medical Instrumentation, a Hyderabad-based medical devices company focused on diagnostic and point-of-care technologies. The investment is aimed at supporting the company’s next phase of growth in product development, manufacturing capacity, and international expansion.
Founded in 2006, Sensa Core operates in the design, development, manufacturing, and distribution of in-vitro diagnostic devices. The company works on an intellectual property-led model and focuses on building diagnostic solutions suited to both domestic and global healthcare needs.
The investment comes at a time when India continues to rely heavily on imported medical devices. Industry estimates indicate that a large share of medical equipment used in the country is sourced from overseas markets, creating opportunities for domestic manufacturers with scalable capabilities.
Company Background
Sensa Core was established by Ravi Kumar Meruva and has built a portfolio of diagnostic products over nearly two decades. Its offerings include glucometers, haemoglobin meters, and arterial blood gas analysers, catering to hospitals, clinics, and diagnostic laboratories.
The company claims its products are used across more than 40,000 hospitals and diagnostic labs in India. In addition to its domestic presence, Sensa Core exports to over 78 countries, giving it a footprint across multiple international markets.
Manufacturing operations are currently based at a facility in the Export Promotion Industrial Park in Pashamylaram, Hyderabad. A new manufacturing unit is also being commissioned at the Medical Device Park in Sultanpur, Hyderabad, to expand capacity and support the development of new products.
Investment Rationale
According to Motilal Oswal Alternates, the investment reflects a broader focus on supporting indigenous manufacturing in the medical devices sector. The firm has highlighted the importance of reducing import dependence and strengthening local production under the broader ‘Make in India’ framework.
The capital infusion is expected to help Sensa Core accelerate research and development, introduce new point-of-care diagnostic solutions, and enhance automation in manufacturing processes. Expansion into additional global markets is also part of the company’s near- to medium-term plans.
From Sensa Core’s perspective, the funding is intended to support scale and innovation while maintaining affordability through local manufacturing and high-volume production. The company has indicated that it plans to deepen its capabilities across engineering, software, electronics, and bio-analytical technologies.
Sector Outlook
India’s medical devices sector has been drawing increased interest from investors as demand for affordable and reliable healthcare solutions grows. Policy support, rising healthcare infrastructure, and a push for domestic manufacturing have further strengthened the sector’s outlook.
Sensa Core’s integrated approach, combining multiple technical disciplines under one roof, positions it within a growing group of Indian medical device companies aiming to compete globally. The partnership with Motilal Oswal Alternates is expected to provide both capital and strategic support.
The transaction was advised by Veda Corporate Advisors. While no specific timelines have been disclosed, the investment marks a significant step for Sensa Core as it looks to expand its role in India’s evolving medical technology landscape and build a stronger global presence.
